Mirum Pharmaceuticals vs Nurix Therapeutics
Mirum Pharmaceuticals is the larger business, with $521m of revenue in fiscal 2025 against $84.0m for Nurix Therapeutics (6.2 times as much). Mirum Pharmaceuticals grew faster (54.7% against 54.0%). Mirum Pharmaceuticals kept more of each dollar of sales as profit: a net margin of -4.5% against -314.9%. Nurix Therapeutics carries less debt relative to equity (0.0% against 98.4%).
| Latest fiscal year | Mirum PharmaceuticalsMIRM, 2025 | Nurix TherapeuticsNRIX, 2025 |
|---|---|---|
| Revenue | $521m | $84.0m |
| Revenue growth | 54.7% | 54.0% |
| Net income | −$23.4m | −$264m |
| Operating margin | -4.2% | -340.2% |
| Net margin | -4.5% | -314.9% |
| Return on equity | -8.6% | -49.6% |
| Free cash flow | $54.9m | −$263m |
| Cash | $297m | $247m |
| Total debt | $310m | $0 |
| Debt to equity | 98.4% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 372 | 317 |
| Market value | $5.61bn | $2.81bn |
| Price vs our value range | — | — |
| Moat score | 10 (Weak) | 11 (Weak) |
| Insider trades, 12 months | 1 buys, 59 sales | 0 buys, 44 sales |